Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Down by 0.6% to Under 10 Trillion Yen in FY2014: IMS
May 22, 2015
- Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
- “4-Company Oligopoly” on Seasonal Flu Vaccines Coming to an End, Era of Mega-Competition Coming to Japan: Dr Yamanishi of BIKEN
May 21, 2015
- Daiichi Sankyo, Takeda to Join in Distribution of Kaketsuken’s Seasonal Influenza Vaccine “to Bolster Stable Supplies”
May 21, 2015
- Otsuka to Launch Abilify Intramuscular Injectable on May 25
May 21, 2015
- Eisai Makes World’s 2nd Launch of Lenvima for Thyroid Cancer in Japan following US
May 21, 2015
- Gilead to Launch Sovaldi on May 25, with Proper Use Promotion by 150 Sales Reps
May 21, 2015
- Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
- R-Tech Ueno Ties Up with Hokkaido University to Develop VAP-1 Inhibitor
May 20, 2015
- Quintiles Acquires Clio Science to Enhance Oncology, CNS Expertise
May 20, 2015
- Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
- Japan’s Biosimilar Market to Rise to 31.4 Billion Yen in 2017: Fuji Keizai
May 19, 2015
- Sanofi Launches Menactra, Preventive Vaccine for Invasive Meningococcal Diseases
May 19, 2015
- Takeda Sees Lower Japan Sales for FY2015 on Generic Pressure
May 18, 2015
- Takeda Incurs Huge Red Ink on Actos Settlement, CEO Says Financial Uncertainty Lessened
May 18, 2015
- Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
- Takeda Discontinues Development of Bipolar Disorder Treatment TAK-375SL
May 18, 2015
- Masanobu Kambara Becomes UCB Japan President
May 18, 2015
- Mochida Terminates License Deal with US Merck for Type 2 Diabetes Treatment
May 18, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…